Hepatic Cirrhosis Clinical Trial
Official title:
A Single-Centre, Open, Controlled, Randomised Cross-Over Study in Healthy Male and Female Volunteers to Evaluate the Pharmacokinetics of Cholyl-Lysyl-Fluorescein (NRL972) in the Presence of Medication-Induced Changes in Cytochrome P450 or Biliary Transporter Proteins. Part B: Interaction With Ursodeoxycholic Acid and Cloxacillin
Verified date | March 2009 |
Source | Norgine |
Contact | n/a |
Is FDA regulated | No |
Health authority | Bulgaria: Ministry of Health |
Study type | Interventional |
A study in healthy volunteers to determine whether different drugs metabolised by the liver have any effects on how NRL972 is processed within the body.
Status | Completed |
Enrollment | 12 |
Est. completion date | October 2006 |
Est. primary completion date | August 2006 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 21 Years to 40 Years |
Eligibility |
Inclusion Criteria: 1. Males or females (females of non-childbearing potential or of childbearing potential while taking medically appropriate contraception) 2. Caucasian 3. Age: 21 - 40 years 4. BW 50 - 100 kg 5. BMI 20 - 26 kg.m-2 6. healthy based on the pre-study examination 7. willing and able to provide informed consent Exclusion Criteria: General - all subjects 1. Previous participation in the trial 2. Participant in any other trial during the last 90 days 3. Donation of blood during the last 60 days or a history of blood loss exceeding 300 mL within the last 3 months 4. History of any clinically relevant allergy (including hypersensitivity to the trial medications) 5. Presence of acute or chronic infection 6. Presence or history of any relevant co-morbidity 7. Resting systolic blood pressure > 160 or < 90 mmHg, diastolic blood pressure > 95 or < 50 mmHg 8. Clinically relevant ECG-abnormalities, prolonged QTc with > 450 msec in males and > 460 msec in females in particular 9. Presence of any relevant abnormality in the laboratory safety tests, especially low haemoglobin, increased liver enzymes 10. Positive serology for HBsAg, anti HBc and anti HCV 11. Positive HIV test 12. Positive alcohol or urine drug test on recruitment (and upon admission) 13. History of alcohol and/or drug abuse and/or daily use of > 30 gr alcohol 14. Smoking more than 15 cigarettes/day or equivalent of other tobacco products 15. Use of prohibited medication 16. Suspicion or evidence that the subject is not trustworthy and reliable 17. Suspicion or evidence that the subject is not able to make a free consent or to understand the information in this regard General - all females 18. Positive pregnancy test 19. Lactating 20. Not using appropriate contraception in pre-menopausal women (note: under the conditions of the present study, women using hormonal contraceptives will be informed that this method is not sufficient during the study and that further i.e. mechanical methods [condom, diaphragm with spermicidal gel] should be us |
Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Country | Name | City | State |
---|---|---|---|
Bulgaria | MHAPT "Zarita Johanna" University Hospital | Sofia |
Lead Sponsor | Collaborator |
---|---|
Norgine |
Bulgaria,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Total clearance by non-compartmental analysis. Apparent terminal disposition half-life t½ by non-compartmental analysis | 4 hours post-dose | No | |
Secondary | Non-compartmental PK-analysis based on the extensive profile (up to last quantifiable data point), the 'short' profile (over the first hour after injection), and the two-point profile based on selected data-pairs over the 1st hour after dosing | 4 hours post-dose | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01349348 -
Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites
|
Phase 3 | |
Active, not recruiting |
NCT04682847 -
Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers
|
||
Recruiting |
NCT05904470 -
A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV
|
Phase 2 | |
Completed |
NCT02138253 -
A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV
|
Phase 2 | |
Recruiting |
NCT02652351 -
Human Umbilical Cord-Mesenchymal Stem Cells for Hepatic Cirrhosis
|
Phase 1 | |
Completed |
NCT00794482 -
Multi-national Cirrhosis Study to Characterise the Association Between the Pharmacokinetics of NRL972 and Disease Severity.
|
Phase 3 | |
Completed |
NCT00856713 -
Clearance of NRL972 in Patients With Cirrhosis and in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT02163512 -
Effect of Beta-adrenergic Blockers on Cardiac Function, Systemic and Splanchnic Haemodynamic and Kidney Function in Cirrhotic Patiets With Refractory Ascites
|
||
Completed |
NCT00006164 -
Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment
|
Phase 3 | |
Completed |
NCT03486912 -
A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis
|
Phase 2 | |
Completed |
NCT00698464 -
Pharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function
|
Phase 1 | |
Completed |
NCT02778425 -
The Treatment of Hepatocirrhosis and Portal Hypertension
|
N/A | |
Completed |
NCT03445208 -
A Study of Experimental Medication BMS-986036 Given to Healthy Participants
|
Phase 1 | |
Completed |
NCT03420768 -
A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C
|
Phase 2 | |
Completed |
NCT03804593 -
HCCBloodTest for Detection of Hepatocellular Carcinoma (HCC)
|
||
Completed |
NCT03712280 -
MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy)
|
Phase 2 | |
Completed |
NCT02230670 -
A Study of IDN-6556 in Subjects With Liver Cirrhosis
|
Phase 2 | |
Completed |
NCT02230683 -
A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
|
Phase 2 | |
Completed |
NCT01135628 -
Hyperproteic Diet Plus Lactobacillus Reuteri and Nitazoxanide in Minimal Hepatic Encephalopathy
|
N/A | |
Completed |
NCT00856869 -
Clearance of NRL972 in Patients With Cirrhosis, Nonalcoholic Steatohepatitis (NASH) and in Healthy Volunteers
|
Phase 1/Phase 2 |